Literature DB >> 11532435

Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion.

Z G Zhang1, L Zhang, W Tsang, A Goussev, C Powers, K L Ho, D Morris, S S Smyth, B S Coller, M Chopp.   

Abstract

Information is lacking regarding dynamic platelet accumulation at the site of the occluded middle cerebral artery (MCA) and the relationship between platelet aggregation in downstream cerebral microvessels and loss of perfusion and vascular integrity of these microvessels. In the present study, we employed a model of embolic MCA occlusion in the rat to simultaneously measure temporal and spatial profiles of platelet accumulation at the site of the embolus occluding the MCA and within downstream cerebral microvessels. We also measured the integrity of microvessels and matrix metalloproteinase (MMP) activity in ischemic brain. Rats (n=36) were subjected to embolic MCA occlusion. Immunohistochemistry was used to detect microvascular integrity, plasminogen activator inhibitor 1 (PAI-1) and the deposition of fibrin. SDS-PAGE zymography was used to measure MMP2 and MMP9 activities. Accumulation of platelets and increases in PAI-1 immunoreactivity at the site of the embolus occluding the MCA were detected 1 h (n=7) and 4 h (n=7) after ischemia, respectively, and numbers of GPIIb/IIIa immunoreactive downstream cerebral microvessels increased significantly (209+/-59; n=7; P<0.05) 4 h after ischemia, suggesting dynamic platelet aggregation. A significant (n=7; P<0.01) diffuse loss of type IV collagen immunoreactivity in microvessels was temporally associated with platelet GPIIb/IIIa immunoreactivity within the vessels. Triple immunostaining revealed that microvessels containing platelet aggregates exhibited loss of type IV collagen immunoreactivity and both intra- and extra-vascular fibrin deposition, suggesting that intravascular platelet aggregation is associated with decreases in the integrity of the microvascular basal lamina and blood-brain barrier leakage. A significant increase (P<0.05) in MMP9 was detected at 4 h (n=3) and 24 h (n=3) after ischemia but levels of MMP2 were not significantly changed in ischemic brain. Our data suggest that dynamic platelet aggregation in ischemic brain may contribute to time-dependent resistance to fibrinolysis. In addition, platelet deposition and increased MMP9 coincided with degradation of type IV collagen and loss of vascular integrity. These data suggest an important role for post-occlusive distal platelet deposition in the pathophysiology of stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532435     DOI: 10.1016/s0006-8993(01)02735-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

1.  Thymosin beta4: a candidate for treatment of stroke?

Authors:  Daniel C Morris; Michael Chopp; Li Zhang; Zheng G Zhang
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

2.  PI3Kγ (Phosphoinositide 3-Kinase-γ) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.

Authors:  Rong Jin; Adam Y Xiao; Jarvis Li; Min Wang; Guohong Li
Journal:  Hypertension       Date:  2019-01       Impact factor: 10.190

3.  A novel atherothrombotic model of ischemic stroke induced by injection of collagen into the cerebral vasculature.

Authors:  Kathryn J Schunke; Thomas K Toung; Jian Zhang; Arvind P Pathak; Jiadi Xu; Jiangyang Zhang; Raymond C Koehler; Nauder Faraday
Journal:  J Neurosci Methods       Date:  2014-10-12       Impact factor: 2.390

4.  Focal embolic cerebral ischemia in the rat.

Authors:  Li Zhang; Rui Lan Zhang; Quan Jiang; Guangliang Ding; Michael Chopp; Zheng Gang Zhang
Journal:  Nat Protoc       Date:  2015-03-05       Impact factor: 13.491

Review 5.  Coagulopathy in traumatic brain injury.

Authors:  Sherman C Stein; Douglas H Smith
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

6.  Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.

Authors:  Fabrício Simão; Tuna Ustunkaya; Allen C Clermont; Edward P Feener
Journal:  Blood       Date:  2017-01-27       Impact factor: 22.113

7.  Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.

Authors:  Xiang Fan; Yinghua Jiang; Zhanyang Yu; Qi Liu; Shuzhen Guo; Xiaochuan Sun; Klaus van Leyen; MingMing Ning; Xiumei Gao; Eng H Lo; Xiaoying Wang
Journal:  Transl Stroke Res       Date:  2017-06-04       Impact factor: 6.829

8.  Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke.

Authors:  Rui Lan Zhang; Chunling Zhang; Li Zhang; Cindi Roberts; Mei Lu; Alissa Kapke; Yisheng Cui; Mitsuyoshi Ninomiya; Toshiaki Nagafuji; Bruce Albala; Zheng Gang Zhang; Michael Chopp
Journal:  Stroke       Date:  2008-07-31       Impact factor: 7.914

9.  Inhibition of CD147 (Cluster of Differentiation 147) Ameliorates Acute Ischemic Stroke in Mice by Reducing Thromboinflammation.

Authors:  Rong Jin; Adam Y Xiao; Rui Chen; D Neil Granger; Guohong Li
Journal:  Stroke       Date:  2017-11-07       Impact factor: 7.914

10.  Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.

Authors:  Li Zhang; Michael Chopp; Longfei Jia; Yisheng Cui; Mei Lu; Zheng Gang Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2009-07-29       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.